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Through its conversion to dopamine by aromatic L-amino acid decarboxylase (AADC), L-3,4-
dihydroxyphenylalanine (L-DOPA) replenishes depleted brain dopamine in Parkinson's disease pa-
tients. We recently identiﬁed GPR143 as a candidate receptor for L-DOPA. In this study, we investigated
the behavioral actions of L-DOPA in wild type (wt) and Gpr143-deﬁcient mice. L-DOPA dose-dependently
(10e100 mg/kg, i.p.) induced ptosis under treatment with 3-hydroxybenzylhydrazine, a centrally acting
AADC inhibitor. This effect was not mimicked by 3-O-methyldopa. L-DOPA-induced ptosis in Gpr143-
deﬁcient mice to a similar extent as in wt mice. These results suggest that L-DOPA induces ptosis in a
GPR143-independent fashion in mice.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
L-3,4-Dihydroxyphenylalanine (L-DOPA) is the standard drug
treatment for Parkinson's disease, the main symptoms of which are
due to nigrostriatal dopamine deﬁciency. Through its conversion to
dopamine by the enzyme aromatic L-amino acid decarboxylase
(AADC), L-DOPA replenishes dopamine (1).
Our previous research suggested that L-DOPA itself is a neuro-
transmitter (2). The impulse-evoked release of endogenous L-DOPA
is dependent on the extracellular concentration of Ca2þ, and it is
blocked by tetrodotoxin, a voltage-dependent Naþ channel blocker
(3). When microinjected into the nucleus tractus solitarii (NTS) of
anesthetized rat, L-DOPA induces depressor and bradycardic re-
sponses that are blocked by L-DOPA ester compounds (2).
An orphan GPR143, which was originally identiﬁed as the pro-
tein ocular albinism 1 (OA1), the gene product of oa1 (4), was
shown to have L-DOPA binding activity. Through GPR143, L-DOPA
appears to be involved in normal development of the retina
pigment epithelium (5). We identiﬁed GPR143 as a candidate re-
ceptor for the L-DOPA actions. Microinjection of L-DOPA into the
NTS causes depressor and bradycardic responses, and these actionsoshima).
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rk.
g by Elsevier B.V. on behalf of Japa
d/4.0/).were attenuated by RNAi knockdown of GPR143 in the NTS, thereby
showing that the effect of L-DOPA was mediated by GPR143 (6).
To elucidate the physiological functions of GPR143, we generated
Gpr143-deﬁcient mice (7) and have performed phenotypic analysis
of these mice. Our studies revealed that, under the inhibition of
central as well as peripheral AADC, L-DOPA-induced ptosis equally in
wild type (wt) and Gpr143-deﬁcient mice. L-DOPA thus appears to
induce ptosis through a GPR143-independent mechanism.2. Materials and methods
All animal care and experimental procedures were conducted in
accordance with NIH guidelines concerning the care and use of
laboratory animals and with the approval of the Animal Care
Committee of the Yokohama City University Graduate School of
Medicine (Approval No. F-A-14-046). Throughout the experimental
procedures, all efforts were made to minimize the number of ani-
mals used and their suffering.
Experiments were performed using male C57BL/6J mice (Orien-
tal Yeast Co., Ltd., Tokyo, Japan).Gpr143-deﬁcientmice (Gpr143/y) in
the C57BL/6J background were used as described previously (7). The
mice (20e30 g) were housed in room in which temperature
(23 ± 1 C) and humidity (55%) were controlled andmaintained on a
12-h light-dark cycle with food and water available ad libitum. All
animals were placed in a cage (20  30 cm) and habituated for 1 h
before an experiment. All drugswere administered intraperitoneallynese Pharmacological Society. This is an open access article under the CC BY-NC-ND
S. Ueda et al. / Journal of Pharmacological Sciences 132 (2016) 109e112110(i.p.). L-DOPAwas purchased fromNacalai Tesque (Kyoto, Japan), and
3-hydroxybenzylhydrazine (NSD-1015), 3-O-methyldopa (3-OMD),
and benserazide from SigmaeAldrich (St. Louis, MO, USA). L-DOPA
and 3-OMD were dissolved in saline containing 0.01 N HCl and 0.1%
dimethyl sulfoxide. Other drugs were dissolved in saline.
Mouse behavioral changes and ptosis were monitored from 0 to
210 min after L-DOPA (10e100 mg/kg) or 3-OMD (60 mg/kg) was
injected. NSD-1015 (100 mg/kg) or benserazide (30 mg/kg) was
injected 10 min before the injection of L-DOPA or 3-OMD. Physo-
stigmine (0.01 mg/kg) was co-injected with L-DOPA. Assessment of
ptosis was performed every 15 min. The state of eyes was assessed
when the mouse was clearly awake and was scored according to a
previously described scale (8): 4, eyes completely closed; 2, eyes
half open; and 0, eyes wide open; with 1 and 3 indicating inter-
mediate values. Fig. 1A illustrates eyes for the scores 0e3; a score of
4 was not seen during these experiments.
For the assessment ofmuscle strength, 2 h after treatmentwith L-
DOPA (60 mg/kg) and NSD-1015 (100 mg/kg), each mouse was
placed on a wire mesh lid. The lid was then shaken to make the
mouse grab the lid. The lid was turned upside down and lifted
40e45 cm above the table, and the time the mouse continued to
hold the lid wasmeasured for amaximum of 60 s.With eachmouse,
this trial was performed three times and the mean value was used.
The tissue contents of dopamine and L-DOPA in the brain were
measured as described previously (3). Mice were sacriﬁced andP
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Fig. 1. L-DOPA induces ptosis-like behavior in mice. (A) Ptosis in mice was scored on a scale
100 mg/kg) after NSD-1015 (100 mg/kg). All values are mean ± SEM (n ¼ 5). ***P < 0.001, v
Summary data on ptosis in mice treated with vehicle (open circle), L-DOPA (60 mg/kg) (clos
i.p.) with benserazide, a peripherally acting AADC inhibitor (50 mg/kg) (closed triangle). All v
NSD-1015.their brains were dissected, placed in ice-chilled 20% trichloroacetic
acid, and homogenized at the time of the peak effect on ptosis, 2 h
after the L-DOPA administration.
The results are presented as means ± SEM of independent ex-
periments. Statistical analysis was performed between two groups
by unpaired Student's t-test or among multiple groups by two-way
ANOVA followed by Bonferroni's multiple comparison test. A P-
value of 0.05 was considered to be signiﬁcant.3. Results
To identify the pharmacological roles of L-DOPA itself, we ﬁrst
performed a behavioral analysis of wt mice after treatment with L-
DOPA (10, 30,100mg/kg, i.p.) or control vehicle under pretreatment
with NSD-1015 (100 mg/kg i.p.), a centrally and peripherally acting
AADC inhibitor. L-DOPA tended to decrease the locomotor activities
in mice (data not shown). L-DOPA also caused ptosis in a dose-
dependent manner (Fig. 1B). To further examine the possible
involvement of dopamine in the behavioral response, we compared
the effects of L-DOPA in mice pretreated with benserazide vs. mice
treated with NSD-1015 (Fig. 1C). L-DOPA and benserazide, a pe-
ripheral AADC inhibitor, increases the contents of dopamine in the
rat brain (9). In contrast to NSD-1015, under treatment with ben-
serazide L-DOPA did not induced ptosis-like behavior.0 15 30 45 60 75 90 10
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from 0 to 3. (B) Summary data on ptosis in mice treated with vehicle or L-DOPA (10, 30,
ehicle vs. L-DOPA 100 mg/kg; ###P < 0.001, #P < 0.05, vehicle vs. L-DOPA 30 mg/kg. (C)
ed circle), or 3-OMD (60 mg/kg) (open triangle) with NSD-1015 and L-DOPA (60 mg/kg,
alues are mean ± SEM (n ¼ 5). ***P < 0.001, **P < 0.01, vehicle vs. L-DOPA 60 mg/kg with
Fig. 3. L-DOPA-induced ptosis in wt and Gpr143/y mice. Summary data on L-DOPA
(60 mg/kg)-induced ptosis in wt (open circle) and Gpr143/y (closed circle) mice pre-
treated with NSD-1015. All values are mean ± SEM (n ¼ 5).
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measured the contents of L-DOPA and dopamine in the whole brain
of mice after NSD-1015 and L-DOPA administration. L-DOPA
increased the content of L-DOPA in the mouse brain (322.9 ± 33.65
pg/mg for vehicle control vs. 2897 ± 668.2 pg/mg for L-DOPA; P <
0.01, Student's t-test). There was no signiﬁcant difference in the
content of dopamine between the L-DOPA and vehicle-treated
groups (2669 ± 102.0 for vehicle control vs. 2786 ± 139.8 pg/mg
for L-DOPA). These ﬁndings further suggest that L-DOPA-induced
ptosis may be caused by L-DOPA and its metabolites, not by dopa-
mine, in mice pretreated with the centrally acting AADC inhibitor.
3-OMD, one of themajor L-DOPAmetabolites (10), was shown to
possess some pharmacological activities (11,12). However, mice
treated with 3-OMD and NSD-1015 showed no changes from the
behavioral baseline when compared to those treated with vehicle
control and NSD-1015 (Fig. 1C).
Ptosis might have been caused by generalized muscle weakness.
We tested the effect of physostigmine, a cholinesterase inhibitor,
against L-DOPA-induced ptosis. Physostigmine reduced L-DOPA-
induced ptosis (Fig. 2). This ﬁnding suggests that L-DOPA-induced
ptosis was caused by impairment of cholinergic transmission in
extraocular muscles. In addition, there was no signiﬁcant difference
in muscle strength assessed by duration in a wire hang test be-
tween the L-DOPA-treated group and the vehicle-treated group
(Data not shown), suggesting that L-DOPA did not induce ptosis
through mechanisms in common with those in muscles of the
whole body. These results suggest that L-DOPA affected some
neuronal circuits that were involved in cholinergic transmission in
the extraocular muscles.
We compared the effect of L-DOPA in wt and Gpr143/y mice. L-
DOPA caused ptosis both in Gpr143/y and wt mice, and there was
no signiﬁcant difference in the extent to which L-DOPA-induced
ptosis between Gpr143/y and wt mice (Fig. 3).4. Discussion
Motor blocks including ptosis (13) can occur as a result of short-
or long-term side effects of L-DOPA treatment (14). In this study, we0 15 30 45 60 75 90 10
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Fig. 2. L-DOPA-induced ptosis was attenuated by physostigmine. Summary data on
ptosis in mice treated with L-DOPA (60 mg/kg) after NSD-1015 with (closed circle) or
without (open circle) physostigmine (0.01 mg/kg), saline after NSD-1015 with (closed
triangle) or without (open triangle) physostigmine. All values are mean ± SEM
(n ¼ 4e5). **P < 0.01, ***P < 0.001, saline þ vehicle vs. saline þ L-DOPA. #P < 0.05,
##P < 0.01, saline þ L-DOPA vs. physostigmine þ L-DOPA.ﬁrst demonstrate that L-DOPA-induced ptosis under the inhibition
of central AADC. Pretreatment with NSD-1015, a centrally and
peripherally acting AADC inhibitor, sufﬁciently inhibited the con-
version of L-DOPA to dopamine in mouse brain. In mice pretreated
with the peripherally acting AADC inhibitor benserazide, L-DOPA-
induced ptosis was hardly observed. These ﬁndings argue against
the notion that dopamine might be involved in L-DOPA-induced
ptosis. 3-OMD is a major L-DOPA metabolite, especially under the
inhibition of AADC, and possesses some pharmacological activities
(11). When intracerebroventricularly administered, 3-OMD in-
creases behavioral activity and stereotypy, which is suppressed by
the dopamine D1/5-receptor antagonist SCH 23390 (11). However,
co-administration of NSD-1015 and 3-OMD did not cause ptosis.
These ﬁndings indicate that L-DOPA-induced ptosis independently
of its conversion to dopamine or 3-OMD. In addition, L-DOPA-
induced ptosis was reduced by cholinesterase inhibitor (Fig. 2),
suggesting that L-DOPA-induced ptosis through reducing cholin-
ergic transmission in the extraocular muscles.
We previously demonstrated that L-DOPA causes depressor and
bradycardic responses through GPR143 in the NTS (6). L-DOPA-
induced depressor and bradycardic responses have been observed
even under inhibition of central AADC (15) and were blocked by L-
DOPA cyclohexyl ester, a competitive antagonist for L-DOPA (2),
and by GPR143 knockdown in the depressor sites of the NTS (6). In
contrast, L-DOPA-induced ptosis was observed in Gpr143/y mice
as well as wt mice. This result clearly indicates that L-DOPA in-
duces ptosis in a GPR143-independent fashion. Several lines of
evidence also indicate non-dopaminergic actions of L-DOPA and
its metabolites (11). Alachkar et al. reported that L-DOPA plus
benserazide and NSD-1015 elicited hyperactive behavior, which
was reduced by the a2C antagonist rauwolscine and the 5-HT2C
agonist MK212 (12). Thus, there appears to be at least three cat-
egories for L-DOPA actions: through the conversion to dopamine
and other L-DOPA metabolites; through GPR143, a speciﬁc re-
ceptor for L-DOPA; and other mechanisms unrelated to dopamine
and GPR143.
In conclusion, this study revealed a new pharmacological effect
of L-DOPA, which is neither through its conversion to dopamine nor
through GPR143. These ﬁndings will help to improve our under-
standing of the pharmacological and untoward actions of L-DOPA in
Parkinson's disease and other neurological disorders.
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